PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke

Fundamental and Clinical Pharmacology

Volumn 28, Issue 3, 2014, Pages 294-302

  Ouk, Thavarak ^a   Potey, Camille ^a   Laprais, Maud ^a   Gautier, Sophie ^a   Hanf, Rémi ^b   Darteil, Raphaël ^b   Staels, Bart ^a   Duriez, Patrick ^a   Bordet, Régis ^a  

^a UNIV LILLE   (France)

^b Parc Eurasante Lille Metropole   (France)

Author keywords

PPARalpha; Statin; Stroke

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; NEUROPROTECTIVE AGENT; NOS2 PROTEIN, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRROLE DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL; BLOOD; BRAIN CORTEX; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; STROKE;

ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEPTANOIC ACIDS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPIDS; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; PPAR ALPHA; PYRROLES; STROKE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84899095959     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12035     Document Type: Article

References (35)

1. Moskowitz M.A., Lo E.H., Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron (2010) 67 181-198.
2. García-Bonilla L., Campos M., Giralt D. et al. Evidence for the efficacy of statins in animal stroke models: a meta-analysis. J. Neurochem. (2012) 122 233-243.
3. Hassan Y., Al-Jabi S., Aziz N., Looi I., Zyoud S. Statin use prior to ischemic stroke onset is associated with decreased in-hospital mortality. Fundam. Clin. Pharmacol. (2011) 25 388-394.
4. Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke (1999) 30 1969-1973.
5. Paumelle R., Staels B. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc. Med. (2008) 18 73-78.
6. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid x receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. (1998) 70 1366-1375.
7. Moreno S., Farioli-Vecchioli S., Ceru M. Immunolocalization of peroxisome proliferator activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience (2004) 123 131-145.
8. Bordet R., Ouk T., Petrault O. et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. (2006) 34 1341-1346.
9. Deplanque D., Gelé P., Pétrault O. et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. (2003) 23 6264-6271.
10. Bordet R., Deplanque D., Maboudou P. et al. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J. Cereb. Blood Flow Metab. (2000) 20 1190-1196.
11. Amarenco P., Bogousslavsky J., Callahan A. et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355 549-559.
12. Adam O., Laufs U. Antioxidative effects of statins. Arch.Toxicol. (2008) 82 885-892.
13. Amantea D., Nappi G., Bernardi G., Bagetta G., Corasaniti M.T. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J. (2009) 276 13-26.
14. Endres M. Statins and stroke. J. Cereb. Blood Flow Metab. (2005) 25 1093-1110.
15. Ifergan I., Wosik K., Cayrol R. et al. Statins reeduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol. (2006) 60 45-55.
16. Zhang L., Zhang Z., Ding G. et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation (2005) 112 3486-3494.
17. Quist-Paulsen P. Statins and inflammation: an update. Curr. Opin. Cardiol. (2010) 25 399-405.
18. Endres M., Laufs U., Liao J., Moskowitz M. Targeting eNOS for stroke protection. Trends Neurosci. (2004) 27 283-289.
19. Endres M., Laufs U., Huang Z. et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. (1998) 95 8880-8885.
20. Roglans N., Sanguino E., Peris C. et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J. Pharmacol. Exp. Ther. (2002) 302 232-239.
21. Inoue I., Itoh F., Aoyagi S. et al. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem. Biophys. Res. Commun. (2002) 290 131-139.
22. Wang G., Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci. Res. (2011) 70 230-237.
23. Yano M., Matsumura T., Senokuchi T. et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. (2007) 100 1442-1451.
24. Paumelle R., Blanquart C., Briand O. et al. Acute antiinflammatory properties of statins involve peroxisome proliferator activated receptor alpha via inhibition of the protein kinase C signaling pathway. Circ. Res. (2006) 98 361-369.
25. Rinaldi B., Donniacuo M., Esposito E. et al. PPARα mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. Br. J. Pharmacol. (2011) 163 609-623.
26. Esposito E., Rinaldi B., Mazzon E. et al. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPARα. J. Neuroinflammation (2012) 9 81.
27. Gray E., Ginty M., Kemp K., Scolding N., Wilkins A. Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. Eur. J. Neurosci. (2011) 33 1421-1432.
28. Delerive P., De Bosscher K., Besnard S. et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. (1999) 274 32048-32054.
29. Cuzzocrea S., Mazzon E., Di Paola R. et al. The role of the peroxisome proliferator-activated receptor-α (PPAR-α) in the regulation of acute inflammation. J. Leukoc. Biol. (2006) 79 999-1010.
30. Touyz R., Schiffrin E. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. (2006) 45 19-28.
31. Guo Q., Wang G., Namura S. Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. (2010) 30 70-78.
32. Ouk T., Laprais M., Bastide M., Mostafa K., Gautier S., Bordet R. Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection. Vascul. Pharmacol. (2009) 51 323-330.
33. Goya K., Sumitani S., Xu X. et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. (2004) 24 658-663.
34. Guo Q., Wang G., Liu X., Namura S. Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. Brain Res. (2009) 1279 121-130.
35. Becker J., Delayre-Orthez C., Frossard N., Pons F. The peroxisome proliferator-activated receptor alpha agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung. Fundam. Clin. Pharmacol. (2012) 26 340-346.